● pepmg Research Desk · Peer-reviewed evidence review
What the research says about SLU-PP-332
A neutral summary of the peer-reviewed literature on SLU-PP-332, a synthetic pan-agonist of the estrogen-related receptors (ERRs) studied as an exercise mimetic entirely in cell and animal models. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- SLU-PP-332 is a synthetic pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), orphan nuclear receptors that help regulate skeletal-muscle exercise capacity and cellular metabolism [1].
- It is described as an "exercise mimetic": in mice, it activates an acute aerobic-exercise-like program and has been reported to improve outcomes in models of obesity and metabolic syndrome and of heart failure [2][3].
- All of the evidence is preclinical, in animals and cell models; a 2026 systematic review of SLU-PP-332 explicitly covers only preclinical studies, and no human trials appear in this corpus [5].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What SLU-PP-332 is
SLU-PP-332 is described in the literature as a small-molecule agonist of the estrogen-related receptors (ERRs), a family of orphan nuclear receptors with three subtypes (ERRα, ERRβ, and ERRγ). Genetic evidence indicates these receptors play an important role in skeletal-muscle exercise capacity and in the regulation of mitochondrial function and metabolism [1]. A notable feature is that SLU-PP-332 has ERRα agonist activity, which had been difficult to achieve with earlier compounds; it was developed to provide a synthetic tool to activate all three ERR subtypes [1].
Because activating ERRs switches on many of the same metabolic programs that physical exercise induces, SLU-PP-332 is characterized as a candidate "exercise mimetic" [2][5]. A related, structurally optimized compound, SLU-PP-915, is studied alongside it [3]. SLU-PP-332 has never been an approved medicine; material sold by research-chemical vendors is not an approved pharmaceutical product and is offered for laboratory and research use only.
What the preclinical research has measured
Preclinical onlyThe foundational work identified SLU-PP-332 as a pan-ERR agonist and showed that it activates an acute aerobic-exercise-like gene program, establishing the basis for the exercise-mimetic idea [1]. Subsequent animal studies examined disease models. In diet-induced obese and ob/ob mice, SLU-PP-332 was administered and its effects on metabolic-syndrome measures were assessed [2]. In heart failure, structure-based design produced pan-ERR agonists (SLU-PP-332 and SLU-PP-915) that were tested for effects on cardiac function and cardiac fatty-acid metabolism in animal models, addressing a prior gap in compounds with pharmacokinetics suitable for in vivo use [3].
Other work is mechanistic and at the cell or tissue level. A study of age-related kidney dysfunction found ERR levels decreased in aging human and mouse kidneys and used a pan-ERR agonist to probe mitochondrial dysfunction and inflammation [4], and a separate study evaluated ERR activation in myoblasts isolated from the skeletal muscle of inactive women, a cell-based experiment rather than an administration trial [6].
A 2026 systematic review drew these together, and it is explicit about the boundary of the evidence: it reviewed the physiological and molecular effects of synthetic pan-ERR agonists, especially SLU-PP-332 and SLU-PP-915, in preclinical models, covering experimental studies in animals and cell models from 2020 to 2024 [5]. No controlled human trial of SLU-PP-332 appears in this corpus.
What the studies report on safety and adverse events
Preclinical onlyBecause there are no human trials of SLU-PP-332 in this corpus, there is no controlled human safety or adverse-event data to report. The animal and cell studies are oriented toward mechanism and efficacy endpoints such as metabolic and cardiac measures, not systematic safety characterization in people.
Two points are worth noting for context. First, the ERRs that SLU-PP-332 activates are broadly involved in metabolism across many tissues (muscle, heart, kidney), so a pan-agonist acts on a widely distributed system, which is a reason careful safety evaluation would be needed before any human conclusions [1][4]. Second, part of the early development challenge was specifically obtaining ERR agonists with pharmacokinetics suitable for in vivo use, a reminder that these are new chemical entities whose behavior in the body was still being characterized in the cited work [3].
None of this is a safety guarantee. SLU-PP-332 is an experimental compound with no controlled human evaluation here, and research-chemical material is not manufactured to pharmacy standards. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence base is characterized as preclinical. SLU-PP-332 has a clear molecular target (pan-ERR agonism) and a coherent set of animal and cell studies suggesting it can switch on exercise-associated metabolic programs and improve measures in models of metabolic and cardiac disease [1][2][3]. What is entirely absent from this corpus is controlled human data, a point the field's own systematic review makes plainly by describing the evidence as preclinical [5].
"Preclinical" is a strict ceiling: an exercise-mimetic mechanism and promising animal results are not evidence that SLU-PP-332 produces exercise-like benefits, or is safe, in people. Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 6
- Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity.
- A Synthetic ERR Agonist Alleviates Metabolic Syndrome.
- Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function.
- Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney.
- Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: a systematic review.
- Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.